The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
September 19th 2024
EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.
September 12th 2024
September 10th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
FDA Approves Kcentra to Reverse Warfarin-Induced Anticoagulation
The US Food and Drug Administration (FDA) today approved Kcentra [prothrombin complex concentrate (human)] for the urgent reversal of anticoagulation induced by vitamin K antagonist (VKA) therapies such as warfarin in adult patients with acute major bleeding.
New Diabetes Management Guidelines Consider Concurrent Conditions
In diagnosing a patient with type 2 diabetes, an endocrinologist or primary care physician may struggle with developing healthy treatment targets when comorbid conditions like obesity and hypoglycemia are at play.
Advances in Treatment Options for Chronic Pain
Chronic pain is a difficult condition to diagnose and manage, especially since most diagnostic measures are subjective and treatment varies from patient to patient. A key to diagnosing and treating chronic pain is to have a strong understanding of the different diagnostic tools and treatment options available.
Omega-3 Therapy Vascepa Reduces Triglycerides in Severe Hypertriglyceridemia Patients
As an adjunct to diet and exercise, Amarin's lipid-regulating agent Vascepa (icosapent ethyl capsules) is indicated to reduce triglyceride levels in adult patients with severe hypertriglyceridemia, or very high triglyceride (TG) levels greater than or equal to 500 milligrams per deciliter (mg/dL).
Blood Thinner Brilinta Treats Acute Coronary Syndrome
Approved by the FDA in July 2011, AstraZeneca's Brilinta (ticagrelor tablets) is a twice-daily treatment to reduce the rate of myocardial infarction and cardiovascular death in adult patients with acute coronary syndrome.